Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Pantoprazole (DB00213)

Also known as: Reflux Disease, Gastro-Esophageal / Oesophageal Reflux / Gastroesophageal Refluxdisease / Gastrooesophageal reflux disease / Gastro-esophageal Reflux Disease / GERD / Esophageal Reflux / Gastroesophageal Reflux Disease (GERD) / Gastro Oesophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD (Gastroesophageal Reflux Disease) / Gastro-Oesophageal Reflux Disease / GERD - Gastro-Esophageal Reflux Disease / GERD Gastroesophageal Reflux Disease / Gastroesophageal Reflux Disease / Gastro Esophageal Reflux Disease / Gastrooesophageal reflux / Gastroesophageal reflux / Acid reflux (finding) / GORD / Gastro-esophageal reflux disease without esophagitis / Gastroesophageal reflux disease (disorder) / Esophageal reflux finding (finding)

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01132638Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux DiseaseTreatment
NCT00336219Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)Treatment
NCT00312806Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)Treatment
NCT00261300Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)Treatment
NCT01400945Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux DiseaseTreatment